MiniMed Group, Inc.: A Recently Spun-Off Diabetes Devices Company With Negative Free Cash Flow

The Quarter in Context

MiniMed closed its first reporting period as a stand-alone public company for the three months ended July 31, 2026, posting net sales of $843 million versus $723 million in the prior-year quarter, a 16.6% reported and 15.8% organic increase. Gross margin compressed 1.5 percentage points to 55.1% because of a higher mix of Simplera sensors, which management discloses currently earn a lower gross margin than legacy and Instinct sensors. Research and development expense fell to $115 million from $125 million, while selling, general and administrative expense rose to $312 million from $283 million as commercialization and information technology costs expanded. GAAP operating income swung from a loss of $13 million to a $5 million profit, and net income reached approximately break-even, compared with a $19 million loss in the prior-year quarter. Cash and cash equivalents stood at $207 million against no long-term debt outstanding, with an undrawn $500 million revolving credit facility in place.

The year-over-year jump in operating profit understates the underlying cash reality. Net cash used in operating activities was $49 million for the quarter versus $141 million in the prior-year quarter, and trailing-twelve-month operating cash flow is still negative at roughly negative $277 million. Capital expenditure of $41 million in the quarter and $207 million over the trailing twelve months continues to absorb working capital that the income statement now only nominally produces. Other operating expense of $36 million, driven by Separation and transition service costs with Medtronic, reminds the reader that the reported figures still reflect one-time carve-out noise. This is, in short, a business showing renewed sales momentum, narrowing GAAP losses, and a heavily burdened cash statement that has yet to convert.

Business Model and Profit Engine

MiniMed develops, manufactures, and markets an integrated diabetes management platform for people with Type 1 and Type 2 diabetes requiring intensive insulin therapy. Customers are individuals, distributors, healthcare providers, and institutions across more than 100 countries, and they buy reusable hardware, single-use consumables, software-enabled dosing algorithms, and digital health services. Revenue is principally transactional and recurring in a hybrid sense: insulin pumps and smart pens are durable purchases while continuous glucose monitoring sensors, infusion sets, reservoirs, and related consumables are replenishment items used continuously after the initial adoption decision. Filing facts show that for the three months ended July 31, 2026 pumps contributed $144 million, consumables $261 million, CGM sensors $431 million, and other $7 million, so consumables plus CGM account for $692 million or roughly 82% of sales.

The profit engine begins with that consumables-and-CGM-heavy revenue base, which produces a 55.1% gross margin and $465 million of gross profit in the quarter. Variable costs are dominated by product cost of $378 million, while fixed and quasi-fixed costs are concentrated in research and development of $115 million and selling, general and administrative expense of $312 million. Total operating expenses of $463 million absorb essentially all of the gross profit, leaving only $5 million of GAAP operating income and effectively zero operating margin. The vertical chain is largely captive: MiniMed sells to end users through durable medical equipment and pharmacy channels, but also benefits from an Integration, Supply and Distribution Agreement with Abbott Diabetes Care, Inc., whose redacted portions suggest a meaningful CGM-related supply or co-distribution role. Pricing power is implied by the consumables and CGM mix, although the disclosed Simplera sensor gross-margin headwind demonstrates that newer products may temporarily compress pricing until scale improves.

Capital intensity is real. Property, plant and equipment of $736 million and goodwill of $2,255 million dominate the asset side, working capital absorbs cash through accounts receivable of $180 million and inventory of $356 million, and trailing-twelve-month capital expenditure of $207 million is not covered by trailing-twelve-month operating cash flow. A segment-level disclosure by product category and geography is provided, but consolidated segment economic detail such as pump versus CGM operating margins is not in the filing and is therefore labeled a data gap. Cross-subsidization between mature and new products appears plausible, because the 55.1% blended gross margin masks the disclosed Simplera drag and supports the inference that older sensors and pumps subsidize the rollout of Simplera. Customer concentration is not quantified in the filing. The principal observable conditions that would weaken the profit engine are continued Simplera margin dilution, accelerating Separation and transition-service costs, and rising litigation or warranty exposure.

Earnings Quality and Cash Conversion

Reported earnings quality improved in the quarter, but cash conversion is the binding constraint. Operating cash flow of negative $49 million is calculated by adding $62 million of non-cash adjustments (chiefly depreciation and amortization of $41 million, stock-based compensation of $10 million, deferred taxes of $2 million, and other items) to break-even net income, then subtracting $111 million of working capital deterioration. The working-capital drag was driven by a $161 million increase in amounts due from Medtronic and a $25 million decline in other operating assets and liabilities, partially offset by a $53 million increase in amounts due to Medtronic and a $25 million rise in accounts payable and accrued liabilities. A clean accounting free-cash-flow proxy, defined as operating cash flow minus total capital expenditure, is therefore negative $90 million in the quarter and negative $484 million over the trailing twelve months, and the filings do not separate maintenance from growth capital expenditure, so the maintenance-versus-growth split is a data gap.

The reported GAAP result is not flattered by one-time gains in a way that would inflate quality; certain litigation charges, net actually swung from a $17 million charge in the prior-year quarter to a $2 million credit because of an accrual reversal, and Italian payback accrual adjustments did not recur this quarter. Conversely, other operating expense, net ballooned from $2 million of income to $36 million of expense because of Separation and transition services, a transitory but cash-relevant headwind that the user must track rather than normalize away. The $4 million income tax provision on $4 million of pre-tax income yields a 96.7% effective rate, distorted by jurisdictional mix and valuation allowances, which is unhelpful for cross-period comparison and limits the usefulness of net income as a quality benchmark. Earnings before interest, taxes, depreciation and amortization, adjusted for stock-based compensation, restructuring, litigation, transaction costs, and Italian payback items, reached $83 million versus $50 million in the prior-year quarter, an internally reported non-GAAP measure that management uses but that an outside investor must discount because it excludes Separation costs that are real cash outflows.

Accounting free cash flow remains -$0.5 billion. In a separate, more conservative owner-earnings sensitivity—not an alternate definition of reported free cash flow—treating TTM stock-based compensation of $0.0 billion as an economic dilution cost produces approximately -$0.5 billion. This is an analytical approximation, not a company-reported measure, and it treats compensation paid in shares as an economic cost even though the cash-flow reconciliation adds it back.

Business Quality, Moat, and Industry Position

MiniMed describes itself as the first company to commercialize all parts of an integrated diabetes management system, including pumps, CGM sensors, consumables, smart dosing software, and digital services. That vertical integration, combined with a regulatory and reimbursement footprint in more than 100 countries and a regulatory clearance library anchored by U.S. Food and Drug Administration approvals and Conformité Européenne markings, is the principal moat evidence in the filings. Filings also reference more than 40 years of category presence, an installed base that drives recurring consumables revenue, and an algorithm that management characterizes as differentiated in real-world time-in-range outcomes. A formal scuttlebutt evidence base, such as independent customer or clinician testimony, is not part of the available record and is therefore labeled as a data gap rather than fabricated.

The competitive context is intense. The 10-K explicitly cites competition from other diabetes device manufacturers, the risk of competing technologies and therapeutic techniques, and pricing pressure for certain products. The $19 billion-plus market the company cites is supported by Seagrove Partners third-party data through February 2026, and management projects market growth above 10% per year through at least 2030. The company's stated dual-channel approach, where the majority of U.S. revenue flows through durable medical equipment rather than pharmacy distribution, is identified as a relative disadvantage versus competitors with broader pharmacy presence. The Single Pane risk factor and Simplera manufacturing and supply risk are also disclosed, suggesting that supply concentration remains a vulnerability. On the evidence available, MiniMed is an important participant in a high-growth category with category-defining history, rather than a dominant bottleneck that dictates industry pricing or supply.

Management and Capital Allocation

Management is led by Chief Executive Officer Que Dallara and Chief Financial Officer Chad Spooner, who signed the most recent periodic reports, with a broader team that includes the heads of clinical, commercial, and supply chain functions referenced in executive offer letters filed as exhibits. The 10-K discloses an explicit governance framework: a Code of Conduct, a Code of Ethics for Senior Financial Officers, a Director Code of Business Conduct and Ethics, a Global Insider Trading Policy, and a Policy for the Recovery of Erroneously Awarded Compensation. The company is also a "controlled company" under Nasdaq rules because Medtronic retains a majority voting interest, and the filings flag related-party arrangements, transition services, and indemnification obligations that warrant careful monitoring.

Capital allocation since the March 9, 2026 separation has been conservative and operationally focused. The quarter shows no share repurchases, no dividend payments, and no disclosed acquisition spending, with $41 million of capital expenditure directed primarily at product development and manufacturing capacity. Stock-based compensation of $10 million is real economic cost and currently dilutes equity, although it represents a small fraction of total operating expense. A $500 million revolving credit facility sits undrawn, providing liquidity headroom, and there is no long-term debt outstanding. Research and development funding arrangements with Blackstone obligate the company to make royalty and minimum payments following U.S. commercial launch of MiniMed Flex, which the filings explicitly describe as an expected significant use of cash during initial commercialization. This is an observable capital-allocation signal that future cash outflows will rise before revenue scales, and it is consistent with the inference that the company will continue to consume, rather than return, capital in the near term.

Valuation and What the Market Already Expects

The dated market capitalization is approximately $6.39 billion at $22.71 per share on September 9, 2026. Shares outstanding were 281,349,931 as of September 3, 2026 per the cover page of the 10-Q. On a trailing-twelve-month basis the company is unprofitable, with negative net income and negative operating cash flow, so a trailing price-to-earnings ratio is not meaningful and a clean price-to-free-cash-flow ratio cannot be formed without inventing a free cash flow the filings do not provide. The market is therefore pricing the equity as a future-earnings story, not a current-earnings asset, and any valuation work must use a normalized or forward cash-flow framework rather than reported multiples.

Reverse-engineering what the market already implies, the $6.39 billion equity value, added to a roughly $1.0 billion rough enterprise-value proxy that the reader can assemble from cash of $207 million and an assumption of zero long-term debt as disclosed, sets a high hurdle for the company to clear. If the market expects MiniMed to converge toward adjusted EBITDA margins that, when applied to a $3.4 billion revenue run rate, produce roughly $300 to $400 million of adjusted EBITDA and the company converts a meaningful share of that into free cash flow over time, then current pricing is consistent with a successful operating turnaround. If the market expects continued negative free cash flow and incremental dilution from stock-based compensation, current pricing is rich. Because we lack a deterministic base scenario from a negative starting free cash flow base, no precise fair value, margin of safety percentage, or implied growth rate is presented here; only the qualitative valuation burden is described.

Ten-Year Cash Flow to Fair Market Value

Direct compounding from the current trailing-twelve-month operating cash flow base of approximately negative $277 million or trailing-twelve-month free cash flow proxy of negative $484 million is invalid as a valuation method because a negative base cannot be grown. A bear, base, and bull normalization is presented instead, with every input labeled as an author assumption rather than an audited figure. The bear path assumes revenue remains roughly flat at a $3.2 to $3.4 billion run rate, free-cash-flow margin remains negative one to two percent of sales because of persistent Separation costs and Simplera margin dilution, and the resulting free cash flow of negative $30 to negative $70 million per year is discounted at an author-assumed 10% cost of capital, producing deeply negative present value and a price target materially below the dated market price.

The base path assumes revenue grows at a 5 to 7% annual rate toward roughly $5.0 to $5.6 billion by year five, free-cash-flow margin gradually expands to 8 to 10% of sales as Separation costs roll off and Simplera scales, and year-five free cash flow reaches roughly $400 to $560 million; a discount at an author-assumed 9 to 10% applied to a normalized year-five and year-ten free-cash-flow stream yields a per-share fair value range that is approximately in line with or modestly above the dated $22.71 share price. The bull path assumes 10%-plus revenue growth driven by international CGM penetration, free-cash-flow margin reaching 13 to 15% by year ten on improving sensor economics and operating leverage, and year-ten free cash flow above $1.0 billion; that case produces a present value that is materially above the dated share price. None of these cases is an audited fair value, and each depends on assumptions that the filings neither confirm nor refute.

Five Value-Investing Lenses

Benjamin Graham Lens

Graham's test for the dated price asks whether the equity trades below a conservatively measured intrinsic value supported by tangible assets and reproducible earnings. Tangible book value is approximately $1.265 billion as of July 31, 2026, computed from stockholders' equity of $3,620 million less goodwill of $2,255 million and intangibles of $100 million. The dated equity value of $6.39 billion is roughly five times tangible book, which is consistent with a growth-quality premium rather than a margin of safety. The filings report negative trailing-twelve-month net income and negative operating cash flow, so the quantitative net-net discipline Graham preferred cannot be applied here. The balance sheet is resilient on a near-term basis because cash of $207 million covers current liabilities of $782 million only modestly and is supported by an undrawn $500 million revolver, but the company has not yet demonstrated the sustained, positive normalized earnings Graham would require. On the available facts the equity does not pass a strict Graham downside-floor test at the dated price.

Benjamin Franklin Lens

The Franklin lens is a modern application of thrift, discipline, compounding, and opportunity cost, and it asks whether capital is being raised, deployed, and preserved with discipline. MiniMed raised primary equity at its March 2026 initial public offering and immediately accessed a $500 million revolving credit facility at separation, so its capital structure today reflects fresh public capital rather than accumulated retained earnings; the accumulated deficit is only negative $116 million because the carve-out structure historically absorbed that history. Capital expenditure of $41 million in the quarter is reasonable relative to revenue, and stock-based compensation of $10 million is modest relative to total operating expense, suggesting dilution is contained for now. The opportunity-cost test asks whether the dated $22.71 share price delivers more value than alternative diabetes-technology or healthcare-equity opportunities of comparable risk, and on this evidence the answer is conditional rather than affirmative, because free cash flow is negative and Adjusted EBITDA conversion to free cash flow has not been demonstrated.

Warren Buffett Lens

Buffett's lens focuses on owner economics, durable moats, and capital allocation by managers who think like owners. MiniMed's owner economics today are negative on a free cash flow basis even though they are positive on a non-GAAP adjusted EBITDA basis, so the owner-economics test fails on current data and depends entirely on whether the company can convert reported earnings into cash. A vertically integrated diabetes platform with regulatory clearances across more than 100 countries and more than 40 years of category presence is a credible durable moat candidate, supported by a high consumables mix that creates a razor-and-blade revenue stream, although competitive pressure and pharmacy distribution disadvantages are explicit risk factors. Capital allocation is conservative: no buybacks, no dividends, modest capital expenditure, an undrawn revolver, and disclosed Blackstone royalty obligations that follow regulatory milestones rather than management whim. The retention of Medtronic as a controlling shareholder is a flag worth monitoring for related-party transactions and transition-service terms, and until adjusted EBITDA reliably translates into free cash flow, the equity does not yet pass an owner-economics test at the dated price.

Charlie Munger Lens

Munger would focus on incentives, inversion, and the willingness to face what could go wrong. The biggest incentive question is whether the controlling-shareholder structure with Medtronic and the related-party transition agreements align with minority shareholders; the filings disclose that Medtronic controls the direction of the business and that conflicts of interest are possible, which Munger would treat as a red flag requiring structural protections rather than trust. Inversion asks how the equity could permanently lose money: a continued negative free-cash-flow trajectory combined with forced Separation-cost absorption, supply interruption at Simplera, or a failed MiniMed Flex commercial launch with minimum-payment obligations to Blackstone would burn cash and pressure the balance sheet. The opportunity-cost question asks whether the dated share price adequately compensates for these tail risks; on available evidence it does not, because a $6.39 billion equity value depends on successful normalization that is plausible but unproven. Bias-wise, an investor must separate the Spin-Co narrative appeal from the negative operating cash flow and avoid extrapolating one quarter of adjusted EBITDA growth into a durable cash-generation profile.

Li Lu Lens

Li Lu would ask whether the business sits inside the analyst's circle of competence, whether the culture supports durable advantage, and whether the equity can survive a permanent loss of capital. The diabetes-device category, with regulatory moats and consumables-driven economics, is conceptually inside a healthcare investor's circle of competence, but the spin-off complexity, the carve-out history, and the controlled-company structure add complexity that a margin-of-safety investor typically avoids. Culture evidence includes an explicit Code of Conduct, a Code of Ethics for Senior Financial Officers, a Director Code of Business Conduct and Ethics, a Global Insider Trading Policy, and a clawback policy, which is a positive observable signal, but the related-party dominance of Medtronic and the prevalence of Separation-related charges means culture must be observed over multiple quarters before drawing strong conclusions. Permanent-loss risk today is real because the company has negative trailing-twelve-month free cash flow and a $207 million cash balance against quarterly operating cash burn averaging over $100 million in recent periods, and the dated $6.39 billion market capitalization provides no margin of safety against a worst-case scenario. On these facts the equity is worth watching rather than buying, because durability has not yet been demonstrated.

Risks, Disconfirming Evidence, and What Would Prove This Thesis Wrong

Prominent growth narratives can amplify attention bias and the price investors are willing to pay before cash flows arrive. That does not negate the operating evidence, but it raises the burden of proof for valuation and makes execution shortfalls more costly. Three observable thesis breakers would force a downward revision. First, a sustained simplification or simplification-related supply interruption that visibly degrades CGM revenue or gross margin, because CGM is the largest product line at $431 million of quarterly revenue and a 1.5-point gross margin compression already traces to the Simplera mix shift. Second, a multi-quarter failure to convert adjusted EBITDA into free cash flow despite Separation-cost normalization, because that would invalidate the bear, base, and bull normalization cases described in the Ten-Year section and re-rate the equity downward toward tangible book. Third, a material adverse change in the Medtronic transition-service, supply, or tax agreements, because the filings disclose ongoing related-party balances of $602 million due from Medtronic and $178 million due to Medtronic that anchor working capital and cash flow timing.

The most likely wrong assumption is that reported adjusted EBITDA of $83 million in the quarter is a clean run-rate; the quarter's reported figure includes a $27 million Separation transaction-cost add-back that is a real cash outflow, and the absence of a clean trailing-twelve-month free-cash-flow conversion makes this assumption vulnerable. Opportunity cost is also a risk: the dated $22.71 share price implies a market capitalization of $6.39 billion, which the reader must weigh against alternative diabetes, healthcare, or broader value-equity opportunities where free cash flow is positive today. Reverse-DCF expectations qualitatively imply the market requires revenue growth toward mid-single digits, adjusted EBITDA margins approaching 20%, and successful free-cash-flow conversion within several years; if those conditions are not visible in the next two quarters of filings, the dated price is hard to defend.

Investment Conclusion

MiniMed Group, Inc. is a recently separated diabetes-devices franchise with strong category positioning, a 16.6% revenue jump in its first stand-alone quarter, and adjusted EBITDA of $83 million, but trailing-twelve-month free cash flow remains negative at roughly $484 million on a working-capital-burdened accounting basis. The dated market capitalization of $6.39 billion at $22.71 per share on September 9, 2026 prices the equity as a successful operating turnaround rather than a current cash generator, and the absence of a deterministic normalized free-cash-flow base precludes a precise margin-of-safety calculation. On the available facts the equity is fairly valued to modestly overvalued, and we would not initiate a full position until the company demonstrates at least two consecutive quarters of positive operating cash flow and clean free-cash-flow conversion. The educational disclaimer that follows is required reading.

This analysis is for educational and informational purposes only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. All figures derive from publicly filed SEC reports and a dated Nasdaq market snapshot, and any forward-looking statements are author inferences rather than company guidance. Investors should perform their own due diligence and consult a qualified financial professional before making investment decisions.